AbCellera expands its multi-target collaboration with Regeneron
koto_feja/E+ via Getty Images

AbCellera (NASDAQ:ABCL) said on Wednesday it has expanded its existing multi-target collaboration with Regeneron (REGN) to find therapeutic antibodies for up to eight targets selected by REGN.
The company said under the agreement, REGN has the right to develop and commercialize therapeutic antibodies resulting from the collaboration.

ABCL will get research payments and is also eligible to receive downstream clinical and regulatory milestone payments and royalties on the net sales of the products.


More on AbCellera Biologics

Seeking Alphaâs Quant Rating on AbCellera Biologics
AbCellera Biologics: Promising Platform, But Watch-And-Wait Approach Advised
AbCellera, Incyte partner for antibody-based cancer drugs
Why did AbCellera Biologics stock dip today? AI-driven rally cools